Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
100 participants
OBSERVATIONAL
2019-12-10
2022-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Effects of Antipsychotic Drugs on Brain Metabolism in Healthy Individuals
NCT02536846
Metformin for Treatment Antipsychotic-induced Metabolic Syndrome in Bipolar Disorder Patients
NCT02644577
Metformin in Co-morbid Diabetes or Prediabetes and Serious Mental Illness
NCT02167620
Heart Rate Variability in Response to Metformin Challenge
NCT02500628
A Clinical Trial Study to Determine the Effect of an Investigational Drug (SEP-363856) Has on the Way That the Drug Metformin Travels Through the Body in People With Schizophrenia.
NCT04865835
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The case-control study will include 2 groups of patients suffering from vertigo of central and peripherial etiology. First group is recruited with patients were diagnosed with peripherial vestibular disorders, such as benign paroxysmal positional vertigo (BPPV), Meniere disease, vestibular neuritis. The proposal number of subjects in the first group is about forty. The second group will consist of forty patients with central vestibular disfunction: vestibular migraine, central positional vertigo etc. The inclusion of patient with persistent postural perceptual dizziness is discussed. Patients will be tested for hydroxyvitamin D and homocysteine in serum using an enzyme-linked immunosorbent assay (ELISA). The perception of the severity of disability was assessed using the Dizziness scale Handicap Inventory (DHI). All patients will undergo psychological test, including tas-26 scale, Beck's Depression Inventory, Spielberg-Hanin'sscale. Statistical analysis was carried out with the Statistical Analysis System (SAS) package. The relationships will be assessed using the chi squared test and logistic regression. The level of significance is set at p \< 0.05. The methods for small samples (Mann-Whitney U ) will be used. It is presumed that differences in vitamin D levels beetween two groups will be considerable.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
OTHER
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
patients with peripherial vestibular disorder
Forty patients with BPPV, vestibular neuritis or another peripherial vestibular disorder
diagnostic blood test
vitamin D deficiency/insufficiency reveal, hyperhomocysteinaemia reveal
neuropsychological test
neuropsychological test, including tas-26 scale, Beck's Depression Inventory, Spielberg-Hanin'scale.
patients with central vestibular disorder
Forty patients vestibular disorder of central origin
diagnostic blood test
vitamin D deficiency/insufficiency reveal, hyperhomocysteinaemia reveal
neuropsychological test
neuropsychological test, including tas-26 scale, Beck's Depression Inventory, Spielberg-Hanin'scale.
healthy controls
twenty healthy control without balance problems
diagnostic blood test
vitamin D deficiency/insufficiency reveal, hyperhomocysteinaemia reveal
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
diagnostic blood test
vitamin D deficiency/insufficiency reveal, hyperhomocysteinaemia reveal
neuropsychological test
neuropsychological test, including tas-26 scale, Beck's Depression Inventory, Spielberg-Hanin'scale.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age:over 18 years old
* complaints of dizziness and insteadiness
Exclusion Criteria
* Severe depression
* Syncopal paroxysms
* Epileptic seizures
* Orthostatic hypotension
* Severe arrhythmia, unstable angina pectoris, acute myocardial infarction
* Pregnancy 8. Alcoholism, substance abuse and drug addiction
* Organic liver and kidney diseases with the development of functional disorders.
* Anemia (hemoglobin \<10.5 g / dl for women and \<11.5 g / dl for men)
* Active oncological process
* Demyelinating and neurodegenerative diseases.
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
I.M. Sechenov First Moscow State Medical University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Anna Bedenko, PhD student
Role: PRINCIPAL_INVESTIGATOR
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Clinic of Neurology and Neurosurgery of I.M. Sechenov First Moscow State Medical University (Sechenov University)
Moscow, , Russia
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Anna Bedenko, PhD student
Role: primary
References
Explore related publications, articles, or registry entries linked to this study.
Bedenko A.S., Antonenko L.М., Barinov A.N. Metabolic disorders in the pathogenesis of various causes of dizziness and instability // Annals of the Russian academy of medical sciences. - 2020. - Vol. 75. - N. 6. - P. 605-608. doi: 10.15690/vramn1244
Bedenko A.S. Vertigo in neurological practice: rare causes and difficult decisions. Medical alphabet. 2019;2(19):34-36. (In Russ.) https://doi.org/10.33667/2078-5631-2019-2-19(394)-34-36
Bedenko A.S. Metabolic factors in pathogenesis of migraine and unsteadiness. Medical alphabet. 2020;(33):18-20. (In Russ.) https://doi.org/10.33667/2078-5631-2020-33-18-20
Bedenko A.S. Vertigo caused by vestibular migraine: current problems of pathogenesis, diagnostics and therapy. Epilepsy and paroxysmal conditions. 2020;12(3):177-181. (In Russ.)https://doi.org/10.17749/2077-8333/epi.par.con.2020.032
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
16-19
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.